Flinders Academic Commons >
Research Publications >
ERA 2010 >
07 - Biomedical and Clinical Research >
1112 - Oncology and Carcinogenesis >
Please use this identifier to cite or link to this item:
|Title: ||Comorbidity, age, race and stage at diagnosis in
colorectal cancer: a retrospective, parallel analysis of two health systems|
|Authors: ||Abbott, David H|
Grambow, Steven C
Zafar, S. Yousuf
Abernethy, Amy Pickar
Marcello, Jennifer E
Herndon II, James E
Rowe, Krista L
Kolimaga, Jane T
Zullig, Leah L
Provenzale, Dawn T
|Issue Date: ||2008|
|Citation: ||Zafar, S., Abernethy, A.P., Abbott, D.H.,
Grambow, S.C., Marcello, J.E., Herndon II, J.E., Rowe, K.L., Kolimaga, J.T., Zullig,
L.L., Patwardhan, M., et al., 2008. Comorbidity, age, race and stage at diagnosis in
colorectal cancer: a retrospective, parallel analysis of two health systems. BMC Cancer,
|Abstract: ||Background :
Stage at diagnosis plays a significant role in colorectal cancer (CRC) survival. Understanding which factors contribute to a more advanced stage at diagnosis is vital to improving overall survival. Comorbidity, race, and age are known to impact receipt of cancer therapy and survival, but the relationship of these factors to stage at diagnosis of CRC is less clear. The objective of this study is to investigate how comorbidity, race and age influence stage of CRC diagnosis.
Two distinct healthcare populations in the United States (US) were retrospectively studied. Using the Cancer Care Outcomes Research and Surveillance Consortium database, we identified CRC patients treated at 15 Veterans Administration (VA) hospitals from 2003–2007. We assessed metastatic CRC patients treated from 2003–2006 at 10 non-VA, fee-for-service (FFS) practices. Stage at diagnosis was dichotomized (non-metastatic, metastatic). Race was dichotomized (white, non-white). Charlson comorbidity index and age at diagnosis were calculated. Associations between stage, comorbidity, race, and age were determined by logistic regression.
342 VA and 340 FFS patients were included. Populations differed by the proportion of patients with metastatic CRC at diagnosis (VA 27% and FFS 77%) reflecting differences in eligibility criteria for inclusion. VA patients were mean (standard deviation; SD) age 67 (11), Charlson index 2.0 (1.0), and were 63% white. FFS patients were mean age 61 (13), Charlson index 1.6 (1.0), and were 73% white. In the VA cohort, higher comorbidity was associated with earlier stage at diagnosis after adjusting for age and race (odds ratio (OR) 0.76, 95% confidence interval (CI) 0.58–1.00; p = 0.045); no such significant relationship was identified in the FFS cohort (OR 1.09, 95% CI 0.82–1.44; p = 0.57). In both cohorts, no association was found between stage at diagnosis and either age or race.
Higher comorbidity may lead to earlier stage of CRC diagnosis. Multiple factors, perhaps including increased interactions with the healthcare system due to comorbidity, might contribute to this finding. Such increased interactions are seen among patients within a healthcare system like the VA system in the US versus sporadic interactions which may be seen with FFS healthcare.|
|Description: ||© 2008 Zafar et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.|
|Appears in Collections:||1112 - Oncology and Carcinogenesis|
1112 - Oncology and Carcinogenesis
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.